Peptide RX

back to claim graph

proof receipt / idea

Biased CXCR4 Partial Agonist for Progenitor Mobilization

A β-arrestin-biased CXCR4 ligand that mobilizes reparative progenitors without the hematologic side effects of full antagonism.

grade C status published receipt a8168bfdd671 proof 17%

what this node claims

Biased CXCR4 Partial Agonist for Progenitor Mobilization

A β-arrestin-biased CXCR4 ligand that mobilizes reparative progenitors without the hematologic side effects of full antagonism.

Open source surface

vertical proof spine

  1. 01 Biased CXCR4 Partial Agonist for Progenitor Mobilization idea / grade C / 55%
  2. 02 CXCR4-TMSB4-axis target / grade B / 70% 1 debt

evidence / risk instrument

38%
thin proof
structure evidence gates risk export lineage 38
low debt pressure 9%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
17%lineagedebt
incomplete spine

proof completeness

17% missing fold, alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

lane
recovery
primary target
CXCR4-TMSB4-axis
proof debt register

Visible limits, not hidden cleanup.

9%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

No upstream proof edge yet.

what it supports

idea names target idea:424da675-7641-45e6-91a0-ce7d20eacd6b -> target:529e55fe-c9ac-4db1-adcc-8cc266ab4833 targets / C / 0.44

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.